ANTWERP, Belgium – November 12, 2025 — Minze Health, a digital health company focused on urinary and bladder conditions, announced a three-year collaboration agreement with Medtronic to integrate the Minze Diary Pod into the sacral neuromodulation (SNM) care pathway for patients with overactive bladder (OAB) in the EMEA region. Under this collaboration, patients receiving Medtronic’s SNM implant will now gain access to Minze’s digital bladder-diary solution, enabling clinicians to collect richer objective data on urinary behaviour, supporting earlier and more confident decisions to initiate therapy, and improving follow-up insights on therapy effectiveness.
Science Significance
From a scientific perspective, the integration of the Minze Diary Pod and Medtronic SNM therapy advances the neuro-urological treatment of OAB by combining neuromodulation with continuous digital monitoring. Overactive bladder is characterised by involuntary bladder contractions and urgency, often leading to decreased quality of life and high treatment burden. By capturing detailed bladder-behaviour metrics remotely, this solution enables improved characterization of patient response to SNM, facilitates earlier intervention, and supports adjustment of stimulation parameters in real time. This convergence of neuromodulation, embedded sensors and digital analytics illustrates a shift toward precision urology therapy, addressing both device and data layers.
Regulatory Significance
Advertisement
Regulatory implications are significant here: the deployment of a combined implant-device plus digital monitoring system requires coordinated oversight of both medical devices and digital health software. Medtronic’s SNM system is already regulated under implantable device frameworks (e.g., CE-Mark in Europe, FDA in the US), while Minze’s diary system may be regulated as a Software as a Medical Device (SaMD). Ensuring compliance with standards for medical-device interoperability, data security (e.g., GDPR), remote monitoring and clinical validation will be crucial. The collaboration supports regulatory readiness for more integrated therapy solutions which span hardware, software and data in regulated urology workflows.
Business Significance
Commercially, the partnership enhances both companies’ value propositions: Medtronic expands its SNM ecosystem by adding a data-driven patient-monitoring component that may improve therapy adoption and outcomes; Minze Health gains access to Medtronic’s global reach and clinical footprint, accelerating its market expansion. The OAB market is large and growing, driven by increasing prevalence of urinary disorders and demand for minimally invasive therapies. By linking neuromodulation with digital monitoring, these companies position themselves competitively in the emerging digital-therapeutics space within urology. This collaboration could also open new business models centred on remote monitoring services, outcome-based reimbursement and therapy-plus-software bundles.
Patients’ Significance
For patients living with overactive bladder, this integration offers the promise of more personalised, better-monitored care. Traditional solutions often rely on patient self-reporting (e.g., paper diaries) which are subject to compliance and accuracy limitations. By utilising a digital home-monitoring device, patients can track urinary behaviour with greater ease and accuracy, enabling clinicians to tailor therapy parameters sooner and less invasively. This may lead to improved symptom control, fewer therapy failures and enhanced quality of life. Additionally, remote monitoring may reduce clinic visits and empower patients with real-time insight into their condition.
Policy Significance
Health-policy implications revolve around the adoption of digital and integrated medical-device solutions in chronic disease management. Europe’s regulatory ecosystem and reimbursement frameworks are increasingly favouring remote-monitoring, value-based care and digital health interventions. This collaboration exemplifies how device manufacturers and digital health firms can combine forces to meet these policy trends, supporting higher standards of care for chronic conditions like OAB while generating data to support health-system decision-making. It also aligns with broader healthcare priorities around aging populations, cost containment, and connected therapies.
The collaboration between Minze Health and Medtronic marks a noteworthy milestone in the evolution of care for overactive bladder—uniting advanced neuromodulation technology with digital monitoring to deliver a more comprehensive and data-driven therapy pathway. As this combined solution rolls out across EMEA, it stands to improve clinical decision-making, patient experience and health-system efficiencies—offering a model for how integrated device and software platforms can reshape specialised care.
Source: Minze Health press release
